Clinical stage biotechnology company developing restorative treatments for people affected by neuropsychiatric & neuroimmunologic disorders
Autobahn Therapeutics has raised $100.0M in total funding. The most recent round was Series C. The last funding was announced in July 2024.
Autobahn Therapeutics's investors include ARCH Venture Partners, Insight Venture Management, LLC., Samsara BioCapital, Canaan Partners, Blue Owl.
Autobahn Therapeutics is headquartered in San Diego, United States.
Clinical stage biotechnology company developing restorative treatments for people affected by neuropsychiatric & neuroimmunologic disorders
Autobahn Therapeutics is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Autobahn Therapeutics — Funding & Investors." VCBacked, July 24, 2024, https://www.vcbacked.co/company/autobahn-therapeutics. Accessed July 20, 2026.
VCBacked. (2024). Autobahn Therapeutics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/autobahn-therapeutics
{{cite web |title=Autobahn Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/autobahn-therapeutics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated